# Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection

> **NCT01965535** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 155 (actual)

## Conditions studied

- HCV Infection

## Interventions

- **DRUG:** LDV/SOF
- **DRUG:** RBV
- **DRUG:** Placebo to match LDV/SOF
- **DRUG:** Placebo to match RBV

## Key facts

- **NCT ID:** NCT01965535
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2014-08
- **Final completion:** 2014-11
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01965535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01965535, "Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT01965535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*